Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441585 | 0.90 | FABP3 (0.47) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5444809 | 0.90 | DPP4 (0.57) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5455705 | 0.88 | DPP4 (0.66) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5447427 | 0.87 | DPP4 (0.67) | DPP4DPP8DPP9ALDH1A1GRIA2 | |
| SCHEMBL5463607 | 0.85 | DPP4 (0.43) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5446358 | 0.83 | DPP4 (0.52) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5455902 | 0.81 | DPP4 (0.68) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL5452153 | 0.81 | DPP4 (0.79) | DPP4DPP8DPP9 | |
| SCHEMBL5741365 | 0.80 | DPP4 (0.55) | DPP4DPP8DPP9KDM4EALDH1A1 | |
| SCHEMBL4113999 | 0.80 | DPP4 (0.44) | DPP4DPP8DPP9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | DPP4 1/4885DPP8 8/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.